A GHRH analog that stimulates natural, pulsatile growth hormone release — once FDA-approved, now widely compounded.
Sermorelin is a synthetic analog of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). It acts directly on pituitary somatotroph cells to stimulate the natural, pulsatile release of growth hormone — mimicking what the hypothalamus does physiologically. This is distinct from administering exogenous growth hormone, which suppresses the body's own production.
Sermorelin was FDA-approved (as Geref) for the diagnosis and treatment of growth hormone deficiency in children. The branded product was discontinued in 2008 for commercial reasons — not safety or efficacy concerns — leaving the drug available only through compounding pharmacies. This history gives sermorelin a rare advantage: an established safety and efficacy record from its FDA-approved period.
In the compounding context, sermorelin is widely prescribed for adult growth hormone deficiency, anti-aging protocols, body composition, sleep quality, and recovery. It is often combined with ipamorelin (a GHRP) for synergistic GH release.
During its FDA-approved period, sermorelin was extensively studied. It demonstrated reliable stimulation of GH secretion and normalization of IGF-1 levels in GH-deficient patients. Unlike exogenous GH, sermorelin preserves the body's feedback mechanisms, reducing risk of excessive GH levels.
In adults, sermorelin studies show improvements in lean body mass, fat reduction, sleep quality, and energy. IGF-1 normalization is a measurable endpoint used to guide dosing. The safety profile from the branded era informs compounding-era use.
📚 Key Reference: PMID: 2541125 (Sermorelin original studies)
Sermorelin is generally well-tolerated. Injection site reactions (redness, swelling) are the most common complaint. Headache, flushing, and dizziness can occur. As a GHRH analog, it stimulates GH release — excessive GH can cause edema, joint pain, carpal tunnel, and impaired glucose tolerance. Regular IGF-1 monitoring is essential. Contraindicated in active malignancy. Consult your provider.
Previously FDA-approved as Geref; discontinued commercially 2008. Now available through compounding pharmacies. The compounding is legal under 503A/503B pharmacy regulations. Not on the FDA 'do not compound' list. One of the most legally and medically well-supported compounded peptides.